Wells Fargo
ACRS icon

Wells Fargo’s Aclaris Therapeutics ACRS Stock Holding History

Wells Fargo’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136K Sell
36,262
-68,203
-65% -$230K ﹤0.01% 4937
2025
Q4 		$314K Buy
104,465
+36,426
+54% +$92K ﹤0.01% 4804
2025
Q3 		$129K Buy
68,039
+5,199
+8% +$9.06K ﹤0.01% 5178
2025
Q2 		$89.2K Buy
62,840
+58,250
+1,269% +$78.8K ﹤0.01% 5254
2025
Q1 		$7.02K Hold
4,590
– – ﹤0.01% 5963
2024
Q4 		$11.4K Hold
4,590
– – ﹤0.01% 5907
2024
Q3 		$5.28K Hold
4,590
– – ﹤0.01% 5908
2024
Q2 		$5.05K Sell
4,590
-21,268
-82% -$25K ﹤0.01% 5874
2024
Q1 		$32.1K Buy
25,858
+5,779
+29% +$6.89K ﹤0.01% 5423
2023
Q4 		$21.1K Buy
20,079
+1,792
+10% +$5.47K ﹤0.01% 5625
2023
Q3 		$125K Sell
18,287
-13,880
-43% -$119K ﹤0.01% 4647
2023
Q2 		$334K Buy
32,167
+14,985
+87% +$136K ﹤0.01% 4245
2023
Q1 		$139K Buy
17,182
+9,596
+126% +$122K ﹤0.01% 4645
2022
Q4 		$119K Buy
7,586
+1,476
+24% +$23.7K ﹤0.01% 4451
2022
Q3 		$97K Sell
6,110
-217
-3% -$3.42K ﹤0.01% 4615
2022
Q2 		$89K Sell
6,327
-33,484
-84% -$469K ﹤0.01% 4703
2022
Q1 		$686K Buy
39,811
+7,013
+21% +$95.7K ﹤0.01% 4171
2021
Q4 		$477K Sell
32,798
-87,751
-73% -$1.33M ﹤0.01% 4699
2021
Q3 		$2.17M Buy
120,549
+119,438
+10,750% +$1.91M ﹤0.01% 3601
2021
Q2 		$20K Sell
1,111
-279
-20% -$6.34K ﹤0.01% 5891
2021
Q1 		$35K Sell
1,390
-31,546
-96% -$617K ﹤0.01% 5978
2020
Q4 		$213K Buy
32,936
+31,719
+2,606% +$134K ﹤0.01% 5050
2020
Q3 		$4K Sell
1,217
-1,019
-46% -$2.28K ﹤0.01% 6036
2020
Q2 		$3K Sell
2,236
-50,114
-96% -$67.1K ﹤0.01% 6045
2020
Q1 		$54K Buy
52,350
+26,213
+100% +$35.7K ﹤0.01% 5307
2019
Q4 		$49K Sell
26,137
-5,876
-18% -$9.74K ﹤0.01% 5513
2019
Q3 		$34K Buy
32,013
+7,047
+28% +$10K ﹤0.01% 5669
2019
Q2 		$54K Sell
24,966
-5,596
-18% -$30.5K ﹤0.01% 5519
2019
Q1 		$184K Buy
30,562
+3,329
+12% +$22.1K ﹤0.01% 4866
2018
Q4 		$201K Buy
27,233
+11,498
+73% +$119K ﹤0.01% 4897
2018
Q3 		$229K Buy
15,735
+854
+6% +$14.6K ﹤0.01% 4936
2018
Q2 		$297K Sell
14,881
-433
-3% -$8K ﹤0.01% 4808
2018
Q1 		$269K Buy
15,314
+87
+0.6% +$1.84K ﹤0.01% 4811
2017
Q4 		$376K Sell
15,227
-26,577
-64% -$647K ﹤0.01% 4593
2017
Q3 		$1.08M Buy
41,804
+921
+2% +$24.7K ﹤0.01% 3794
2017
Q2 		$1.11M Buy
40,883
+28,524
+231% +$775K ﹤0.01% 3666
2017
Q1 		$369K Buy
12,359
+5,900
+91% +$170K ﹤0.01% 4445
2016
Q4 		$175K Buy
6,459
+3,193
+98% +$81.4K ﹤0.01% 4840
2016
Q3 		$84K Buy
3,266
+1,617
+98% +$34.3K ﹤0.01% 5017
2016
Q2 		$30K Sell
1,649
-209
-11% -$4.14K ﹤0.01% 5371
2016
Q1 		$30K Buy
1,858
+198
+12% +$3.78K ﹤0.01% 5398
2015
Q4 		$45K Buy
+1,660
New +$32.3K ﹤0.01% 5321

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wells Fargo's ACRS Position: Q1 2026 in Review

Wells Fargo reduced its Aclaris Therapeutics (ACRS) stake by 65% in Q1 2026, selling an estimated $230K and leaving 36,262 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4937.

Wells Fargo first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.17M in Q3 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Wells Fargo held 36,262 shares of Aclaris Therapeutics worth $136K as of Q1 2026.
  • Wells Fargo sold 68,203 Aclaris Therapeutics shares in Q1 2026, an estimated $230K.
  • Aclaris Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4937 holding.
  • Wells Fargo first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Wells Fargo's Aclaris Therapeutics position peaked at $2.17M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.